
89bio, Inc. (NASDAQ: ETNB) related to its sale to Roche Holdings, Inc. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones.